🎗️ Lymph Node Status & Treatment Intensity Simulator

Sentinel Lymph Node Biopsy & Axillary Dissection

Nodes are sampled to check for regional spread.

• 1–3: Sentinel nodes removed (first-drainage nodes)
• I–III: Axillary levels (anatomic tiers)
• Dye + tracer: Detection method (blue dye / radiotracer)
• 10–25: Full dissection nodes (if SLNB positive)

Why nodes are checked first

Nodes are the first stop for spreading cancer cells.

Sentinel node concept

The sentinel node predicts the rest of the chain.

From biopsy to staging

Pathology result feeds directly into N-stage.

N0 — No Positive Axillary Nodes

No cancer cells found in any sampled node.

• 0: Positive nodes (of nodes sampled)
• ~96%: 5-yr survival (N0) (baseline estimate)
• Minimal: Typical therapy (often endocrine only)
• Rarely: Regional RT needed (breast-only field usual)

What N0 means

Disease appears confined to the primary breast tumor.

Baseline prognosis

N0 carries the best outlook of all N-stages.

Treatment implications

Systemic therapy is guided mainly by tumor biology.

N1 — One To Three Positive Axillary Nodes

A small number of axillary nodes now involved.

• 1–3: Positive nodes (axillary only)
• ~86%: 5-yr survival (N1) (baseline estimate)
• Standard chemo: Typical therapy (plus whole-breast RT)
• Often: Regional RT needed (depends on other factors)

Early regional spread

Cancer has begun moving beyond the breast.

Why intensity rises

More nodes signal more micrometastatic risk.

Common regimen shift

Chemotherapy is added for most N1 patients.

N2/N3 — Extensive Regional Nodal Disease

Four or more nodes, or extra node groups, involved.

• 4+: Positive nodes (or extra groups)
• ~55%: 5-yr survival (N3) (baseline estimate)
• Intensive/maximal: Typical therapy (chemo + extended RT)
• Infraclav./int. mammary: Extra groups (beyond axilla)

Beyond the axilla

Spread reaches infraclavicular or internal mammary nodes.

Higher-risk disease

More node groups implies broader micrometastatic reach.

Escalated treatment

Chemotherapy and radiation fields both expand.

Nodal Burden, Treatment Intensity & Prognosis

More positive nodes mean stronger therapy, lower baseline odds.

• N0–N3: N-stage range (increasing burden)
• 96%→38%: Prognosis spread (model estimate range)
• 4 tiers: Therapy escalation (minimal to maximal)
• Breast→extended: Radiation field growth (with rising N-stage)

Nodal burden drives intensity

Each added positive node nudges therapy stronger.

Micrometastatic risk logic

More nodes suggest disease beyond what is visible.

Putting it together

N-stage is a key input to the whole treatment plan.